The post Key Results from the CHRONOS Multicentre Retrospective Cohort Study Describing Patient Outcomes in Third-Line Acute Gastrointestinal GvHD appeared first on 91桃色视频.

The post THRASSA, A Multicenter, Open-label Study Evaluating The Safety, Tolerability And Efficacy Of MaaT013 In Ruxolitinib-refractory Or Intolerant Paediatric/ Adolescent Participants With Gastrointestinal Acute Graft-versus-Host Disease appeared first on 91桃色视频.

The post MaaT033 For Gut Microbiota Optimization To Improve Survival After Allogenic HCT: The PHOEBUS Trial appeared first on 91桃色视频.

The post MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study appeared first on 91桃色视频.

The post MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice appeared first on 91桃色视频.

The post MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity appeared first on 91桃色视频.

The post Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe appeared first on 91桃色视频.

The post MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial appeared first on 91桃色视频.

The post PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeneic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only) appeared first on 91桃色视频.

The post Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors appeared first on 91桃色视频.